GRAIL, Inc. (GRAL) Securities Class Action Filed Following NHS-Galleri Trial Failure and $2.2 Billion Market Cap Loss -- HBSS

GRAIL, Inc. faced a securities class action lawsuit after its NHS-Galleri trial failed to meet its primary endpoint on February 20, 2026, resulting in a $2.2 billion market capitalization loss and over 50% stock price decline. The lawsuit alleges GRAIL misled investors about the trial's design and likelihood of success, with the company later admitting it should have allowed for a longer follow-up period than the three years originally touted.